The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
Chen X, Adhikary G, Newland JJ, Xu W, Ma E, Naselsky W, Eckert RL
Mol Carcinog. 2023 Jan;62(1):90-100. doi: 10.1002/mc.23446. Epub 2022 Jul 18.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.